Ethical problems of evaluating a new treatment for melioidosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 14644975.
- Also identified by PMC identifier 286254.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
When mortality from melioidosis fell sharply after multiple changes in management at an Australian hospital, doctors wanted to identify whether a new drug was responsible. But designing a trial that was ethically acceptable proved impossible
Medical subject headings
- Granulocyte Colony-Stimulating Factor
- Melioidosis
- Randomized Controlled Trials as Topic